肿瘤是威胁我国居民生命健康最重要的一类疾病，每年有接近400万新发肿瘤患者。其中的晚期肿瘤患者，缺乏有效治疗手段，只能靠用药维持生命。但我国的现状是一方面是患者对前沿最新抗肿瘤药物的需求，另一方面是前沿新药带来的沉重经济负担。患者以参加临床试验的形式得到治疗是一种满足制药企业和肿瘤患者双方利益的形式，在国外已广泛开展，但国内患者对临床试验相对陌生，因有所顾虑而未充分接纳这种形式的治疗。
为打破肿瘤患者和制药企业的隔阂，实现双方的获益。爱渡公司从成立以来全面启动抗肿瘤药物临床试验志愿者招募服务并同步拓展自媒体/新媒体领域，创立“ai帮帮”和“ai帮帮之声”品牌，分别承担志愿者招募和肿瘤医学知识科普的职能。
爱渡公司向制药企业提供的志愿者招募服务与传统模式不同，通过向患者传递专业的医学知识和最新的医药产业信息打破患者和医疗服务提供方的信息不对等，帮助肿瘤患者理解和接纳临床试验，从而主动选择临床试验。爱渡公司在患者参加临床试验的准备阶段，提供免费的代理服务，减少肿瘤患者额外的负担。
迄今为止，爱渡公司已与复星医药、复宏汉霖、信达生物、基石药业、百济神州、和黄药业、康方天成、海和生物、泰州翰中、金赛药业、诺诚健华、奥鸿药业、嘉和生物药业等多家拥有抗肿瘤药物独立研发能力的内资制药企业达成合作。项目涵盖多种实体瘤(如肺癌、食管癌、结直肠癌、胃癌、胆道癌、肝癌、乳腺癌、卵巢癌、宫颈癌、甲状腺癌、头颈癌、黑色素瘤、神经内分泌瘤等)、淋巴瘤(经典霍奇金淋巴瘤、成熟B细胞淋巴瘤、NK/T细胞淋巴瘤、外周T细胞淋巴瘤等)和血液肿瘤(骨髓增生异常综合征、急性髓系白血病等)。旗下品牌“ai帮帮”和“ai帮帮之声”已成功覆盖10万以上的精准肿瘤用户及家属，践行了爱渡公司的成立初衷：为患者提供治疗的新希望，为医生积累最新药物使用经验，为制药企业加速临床试验进度。
Shanghai Aidu Medical Technology Co., Ltd. (hereinafter referred to as Aidu Medical) was established in March 2018, focusing on the recruitment of clinical trial participants of new anti-tumor drugs, and wascommitted to be the best partner for Chinese innovative pharmaceutical companies of anti-tumor drugs.
In order to break the gap between cancer patients and pharmaceutical companies and realize the benefits of both parties, Aidu has launched a comprehensive recruitment of antitumor drug clinical trial volunteer recruitment services since its establishment, and expanded the self-media/new media field simultaneously, creating "ai_jiuzhu" and "aibbzs" brand respectively, which are responsible for volunteer recruitment and oncology knowledge popularization.
So far, Aidu Medical has reached cooperation with a number of domestic-funded pharmaceutical companies with independent R&D capabilities of anti-tumor drugs, including Fosunpharma, Henlius, Innovent, CStone Pharmaceuticals, BeiGene, Hutchison Pharmaceuticals, Akeso Biopharma, HaiHe Biopharma, Taizhou Hanzhong Biomedical, GenSci Biopharma, InnoCare Pharmaceuticals , Avanc Pharmaceuticals, Jiahe Biological Pharmaceuticals, ect. The brands of "ai_jiuzhu" and "aibbzs" have successfully covered more than 100,000 precision tumor users and their families, fulfilling the original intention of Aidu Medical: to provide new hopes for cancer patients, to accumulate new drug using experience for doctors and to accelerate the progress of clinical trials for pharmaceutical companies.
